Global Biomacromolecule CDMO Supply, Demand and Key Producers, 2023-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,480	161 Pages	GlobalInfoResearch	December, 2023	GFSH18398293

Best Price Guarantee
Price	from $4,480
Length	161 Pages
Publisher	GlobalInfoResearch
Published Date	December, 2023
SKU	GFSH18398293

Global Biomacromolecule CDMO Supply, Demand and Key Producers, 2023-2029

The global Biomacromolecule CDMO market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The macromolecule CDMO industry refers to drugs that rely on cell biosynthesis, usually with a molecular weight greater than 1,000. Macromolecule CDMO mainly focuses on biopharmaceuticals, and the intermediates are relatively unified, mainly including some raw materials, protein and antibody preparation, stable cell lines and process development, and the production and research and development of biological preparations.

This report studies the global Biomacromolecule CDMO demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Biomacromolecule CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biomacromolecule CDMO that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Biomacromolecule CDMO total market, 2018-2029, (USD Million)

Global Biomacromolecule CDMO total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Biomacromolecule CDMO total market, key domestic companies and share, (USD Million)

Global Biomacromolecule CDMO revenue by player and market share 2018-2023, (USD Million)

Global Biomacromolecule CDMO total market by Type, CAGR, 2018-2029, (USD Million)

Global Biomacromolecule CDMO total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Biomacromolecule CDMO market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Wuxi Biologics (Cayman) Inc., Catalent, Thermo Fisher Scientific, Samsung Biologics, Rentschler Biopharma, Baxter Biopharma Solutions, Merck BioReliance and Cytovance Biologics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Biomacromolecule CDMO market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Biomacromolecule CDMO Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Biomacromolecule CDMO Market, Segmentation by Type

Biologics CDMO

Viral Vaccine Production CDMO

Analyze and Test CDMOs

Others

Global Biomacromolecule CDMO Market, Segmentation by Application

Drug Development

Vaccine Production

Technology Transfer

Others

Companies Profiled:

Lonza

Wuxi Biologics (Cayman) Inc.

Catalent

Thermo Fisher Scientific

Samsung Biologics

Rentschler Biopharma

Baxter Biopharma Solutions

Merck BioReliance

Cytovance Biologics

AGC Biologics

Abzena

Emergent BioSolutions

ProBioGen

Goodwin Biotechnology

KBI Biopharma

Asymchem Laboratories (Tianjin) Co., Ltd.

Shanghai Chempartner Lifescience Co., Ltd.

Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd.

Genscript Biotech

Beijing Joinn Biologics Co., Ltd.

Key Questions Answered

1. How big is the global Biomacromolecule CDMO market?

2. What is the demand of the global Biomacromolecule CDMO market?

3. What is the year over year growth of the global Biomacromolecule CDMO market?

4. What is the total value of the global Biomacromolecule CDMO market?

5. Who are the major players in the global Biomacromolecule CDMO market?

1 Supply Summary: 1.1 Biomacromolecule CDMO Introduction; 1.2 World Biomacromolecule CDMO Market Size & Forecast (2018 & 2022 & 2029); 1.3 World Biomacromolecule CDMO Total Market by Region (by Headquarter Location); 1.3.1 World Biomacromolecule CDMO Market Size by Region (2018-2029), (by Headquarter Location); 1.3.2 United States Biomacromolecule CDMO Market Size (2018-2029); 1.3.3 China Biomacromolecule CDMO Market Size (2018-2029); 1.3.4 Europe Biomacromolecule CDMO Market Size (2018-2029); 1.3.5 Japan Biomacromolecule CDMO Market Size (2018-2029); 1.3.6 South Korea Biomacromolecule CDMO Market Size (2018-2029); 1.3.7 ASEAN Biomacromolecule CDMO Market Size (2018-2029); 1.3.8 India Biomacromolecule CDMO Market Size (2018-2029); 1.4 Market Drivers, Restraints and Trends; 1.4.1 Biomacromolecule CDMO Market Drivers; 1.4.2 Factors Affecting Demand; 1.4.3 Biomacromolecule CDMO Major Market Trends
2 Demand Summary: 2.1 World Biomacromolecule CDMO Consumption Value (2018-2029); 2.2 World Biomacromolecule CDMO Consumption Value by Region; 2.2.1 World Biomacromolecule CDMO Consumption Value by Region (2018-2023); 2.2.2 World Biomacromolecule CDMO Consumption Value Forecast by Region (2024-2029); 2.3 United States Biomacromolecule CDMO Consumption Value (2018-2029); 2.4 China Biomacromolecule CDMO Consumption Value (2018-2029); 2.5 Europe Biomacromolecule CDMO Consumption Value (2018-2029); 2.6 Japan Biomacromolecule CDMO Consumption Value (2018-2029); 2.7 South Korea Biomacromolecule CDMO Consumption Value (2018-2029); 2.8 ASEAN Biomacromolecule CDMO Consumption Value (2018-2029); 2.9 India Biomacromolecule CDMO Consumption Value (2018-2029)
3 World Biomacromolecule CDMO Companies Competitive Analysis: 3.1 World Biomacromolecule CDMO Revenue by Player (2018-2023); 3.2 Industry Rank and Concentration Rate (CR); 3.2.1 Global Biomacromolecule CDMO Industry Rank of Major Players; 3.2.2 Global Concentration Ratios (CR4) for Biomacromolecule CDMO in 2022; 3.2.3 Global Concentration Ratios (CR8) for Biomacromolecule CDMO in 2022; 3.3 Biomacromolecule CDMO Company Evaluation Quadrant; 3.4 Biomacromolecule CDMO Market: Overall Company Footprint Analysis; 3.4.1 Biomacromolecule CDMO Market: Region Footprint; 3.4.2 Biomacromolecule CDMO Market: Company Product Type Footprint; 3.4.3 Biomacromolecule CDMO Market: Company Product Application Footprint; 3.5 Competitive Environment; 3.5.1 Historical Structure of the Industry; 3.5.2 Barriers of Market Entry; 3.5.3 Factors of Competition; 3.6 Mergers, Acquisitions Activity
4 United States VS China VS Rest of the World (by Headquarter Location): 4.1 United States VS China: Biomacromolecule CDMO Revenue Comparison (by Headquarter Location); 4.1.1 United States VS China: Biomacromolecule CDMO Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location); 4.1.2 United States VS China: Biomacromolecule CDMO Revenue Market Share Comparison (2018 & 2022 & 2029); 4.2 United States Based Companies VS China Based Companies: Biomacromolecule CDMO Consumption Value Comparison; 4.2.1 United States VS China: Biomacromolecule CDMO Consumption Value Comparison (2018 & 2022 & 2029); 4.2.2 United States VS China: Biomacromolecule CDMO Consumption Value Market Share Comparison (2018 & 2022 & 2029); 4.3 United States Based Biomacromolecule CDMO Companies and Market Share, 2018-2023; 4.3.1 United States Based Biomacromolecule CDMO Companies, Headquarters (States, Country); 4.3.2 United States Based Companies Biomacromolecule CDMO Revenue, (2018-2023); 4.4 China Based Companies Biomacromolecule CDMO Revenue and Market Share, 2018-2023; 4.4.1 China Based Biomacromolecule CDMO Companies, Company Headquarters (Province, Country); 4.4.2 China Based Companies Biomacromolecule CDMO Revenue, (2018-2023); 4.5 Rest of World Based Biomacromolecule CDMO Companies and Market Share, 2018-2023; 4.5.1 Rest of World Based Biomacromolecule CDMO Companies, Headquarters (States, Country); 4.5.2 Rest of World Based Companies Biomacromolecule CDMO Revenue, (2018-2023)
5 Market Analysis by Type: 5.1 World Biomacromolecule CDMO Market Size Overview by Type: 2018 VS 2022 VS 2029; 5.2 Segment Introduction by Type; 5.2.1 Biologics CDMO; 5.2.2 Viral Vaccine Production CDMO; 5.2.3 Analyze and Test CDMOs; 5.2.4 Others; 5.3 Market Segment by Type; 5.3.1 World Biomacromolecule CDMO Market Size by Type (2018-2023); 5.3.2 World Biomacromolecule CDMO Market Size by Type (2024-2029); 5.3.3 World Biomacromolecule CDMO Market Size Market Share by Type (2018-2029)
6 Market Analysis by Application: 6.1 World Biomacromolecule CDMO Market Size Overview by Application: 2018 VS 2022 VS 2029; 6.2 Segment Introduction by Application; 6.2.1 Drug Development; 6.2.2 Vaccine Production; 6.2.3 Technology Transfer; 6.2.4 Others; 6.2.5 Others; 6.3 Market Segment by Application; 6.3.1 World Biomacromolecule CDMO Market Size by Application (2018-2023); 6.3.2 World Biomacromolecule CDMO Market Size by Application (2024-2029); 6.3.3 World Biomacromolecule CDMO Market Size by Application (2018-2029)
7 Company Profiles: 7.1 Lonza; 7.1.1 Lonza Details; 7.1.2 Lonza Major Business; 7.1.3 Lonza Biomacromolecule CDMO Product and Services; 7.1.4 Lonza Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.1.5 Lonza Recent Developments/Updates; 7.1.6 Lonza Competitive Strengths & Weaknesses; 7.2 Wuxi Biologics (Cayman) Inc.; 7.2.1 Wuxi Biologics (Cayman) Inc. Details; 7.2.2 Wuxi Biologics (Cayman) Inc. Major Business; 7.2.3 Wuxi Biologics (Cayman) Inc. Biomacromolecule CDMO Product and Services; 7.2.4 Wuxi Biologics (Cayman) Inc. Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.2.5 Wuxi Biologics (Cayman) Inc. Recent Developments/Updates; 7.2.6 Wuxi Biologics (Cayman) Inc. Competitive Strengths & Weaknesses; 7.3 Catalent; 7.3.1 Catalent Details; 7.3.2 Catalent Major Business; 7.3.3 Catalent Biomacromolecule CDMO Product and Services; 7.3.4 Catalent Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.3.5 Catalent Recent Developments/Updates; 7.3.6 Catalent Competitive Strengths & Weaknesses; 7.4 Thermo Fisher Scientific; 7.4.1 Thermo Fisher Scientific Details; 7.4.2 Thermo Fisher Scientific Major Business; 7.4.3 Thermo Fisher Scientific Biomacromolecule CDMO Product and Services; 7.4.4 Thermo Fisher Scientific Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.4.5 Thermo Fisher Scientific Recent Developments/Updates; 7.4.6 Thermo Fisher Scientific Competitive Strengths & Weaknesses; 7.5 Samsung Biologics; 7.5.1 Samsung Biologics Details; 7.5.2 Samsung Biologics Major Business; 7.5.3 Samsung Biologics Biomacromolecule CDMO Product and Services; 7.5.4 Samsung Biologics Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.5.5 Samsung Biologics Recent Developments/Updates; 7.5.6 Samsung Biologics Competitive Strengths & Weaknesses; 7.6 Rentschler Biopharma; 7.6.1 Rentschler Biopharma Details; 7.6.2 Rentschler Biopharma Major Business; 7.6.3 Rentschler Biopharma Biomacromolecule CDMO Product and Services; 7.6.4 Rentschler Biopharma Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.6.5 Rentschler Biopharma Recent Developments/Updates; 7.6.6 Rentschler Biopharma Competitive Strengths & Weaknesses; 7.7 Baxter Biopharma Solutions; 7.7.1 Baxter Biopharma Solutions Details; 7.7.2 Baxter Biopharma Solutions Major Business; 7.7.3 Baxter Biopharma Solutions Biomacromolecule CDMO Product and Services; 7.7.4 Baxter Biopharma Solutions Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.7.5 Baxter Biopharma Solutions Recent Developments/Updates; 7.7.6 Baxter Biopharma Solutions Competitive Strengths & Weaknesses; 7.8 Merck BioReliance; 7.8.1 Merck BioReliance Details; 7.8.2 Merck BioReliance Major Business; 7.8.3 Merck BioReliance Biomacromolecule CDMO Product and Services; 7.8.4 Merck BioReliance Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.8.5 Merck BioReliance Recent Developments/Updates; 7.8.6 Merck BioReliance Competitive Strengths & Weaknesses; 7.9 Cytovance Biologics; 7.9.1 Cytovance Biologics Details; 7.9.2 Cytovance Biologics Major Business; 7.9.3 Cytovance Biologics Biomacromolecule CDMO Product and Services; 7.9.4 Cytovance Biologics Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.9.5 Cytovance Biologics Recent Developments/Updates; 7.9.6 Cytovance Biologics Competitive Strengths & Weaknesses; 7.10 AGC Biologics; 7.10.1 AGC Biologics Details; 7.10.2 AGC Biologics Major Business; 7.10.3 AGC Biologics Biomacromolecule CDMO Product and Services; 7.10.4 AGC Biologics Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.10.5 AGC Biologics Recent Developments/Updates; 7.10.6 AGC Biologics Competitive Strengths & Weaknesses; 7.11 Abzena; 7.11.1 Abzena Details; 7.11.2 Abzena Major Business; 7.11.3 Abzena Biomacromolecule CDMO Product and Services; 7.11.4 Abzena Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.11.5 Abzena Recent Developments/Updates; 7.11.6 Abzena Competitive Strengths & Weaknesses; 7.12 Emergent BioSolutions; 7.12.1 Emergent BioSolutions Details; 7.12.2 Emergent BioSolutions Major Business; 7.12.3 Emergent BioSolutions Biomacromolecule CDMO Product and Services; 7.12.4 Emergent BioSolutions Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.12.5 Emergent BioSolutions Recent Developments/Updates; 7.12.6 Emergent BioSolutions Competitive Strengths & Weaknesses; 7.13 ProBioGen; 7.13.1 ProBioGen Details; 7.13.2 ProBioGen Major Business; 7.13.3 ProBioGen Biomacromolecule CDMO Product and Services; 7.13.4 ProBioGen Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.13.5 ProBioGen Recent Developments/Updates; 7.13.6 ProBioGen Competitive Strengths & Weaknesses; 7.14 Goodwin Biotechnology; 7.14.1 Goodwin Biotechnology Details; 7.14.2 Goodwin Biotechnology Major Business; 7.14.3 Goodwin Biotechnology Biomacromolecule CDMO Product and Services; 7.14.4 Goodwin Biotechnology Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.14.5 Goodwin Biotechnology Recent Developments/Updates; 7.14.6 Goodwin Biotechnology Competitive Strengths & Weaknesses; 7.15 KBI Biopharma; 7.15.1 KBI Biopharma Details; 7.15.2 KBI Biopharma Major Business; 7.15.3 KBI Biopharma Biomacromolecule CDMO Product and Services; 7.15.4 KBI Biopharma Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.15.5 KBI Biopharma Recent Developments/Updates; 7.15.6 KBI Biopharma Competitive Strengths & Weaknesses; 7.16 Asymchem Laboratories (Tianjin) Co., Ltd.; 7.16.1 Asymchem Laboratories (Tianjin) Co., Ltd. Details; 7.16.2 Asymchem Laboratories (Tianjin) Co., Ltd. Major Business; 7.16.3 Asymchem Laboratories (Tianjin) Co., Ltd. Biomacromolecule CDMO Product and Services; 7.16.4 Asymchem Laboratories (Tianjin) Co., Ltd. Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.16.5 Asymchem Laboratories (Tianjin) Co., Ltd. Recent Developments/Updates; 7.16.6 Asymchem Laboratories (Tianjin) Co., Ltd. Competitive Strengths & Weaknesses; 7.17 Shanghai Chempartner Lifescience Co., Ltd.; 7.17.1 Shanghai Chempartner Lifescience Co., Ltd. Details; 7.17.2 Shanghai Chempartner Lifescience Co., Ltd. Major Business; 7.17.3 Shanghai Chempartner Lifescience Co., Ltd. Biomacromolecule CDMO Product and Services; 7.17.4 Shanghai Chempartner Lifescience Co., Ltd. Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.17.5 Shanghai Chempartner Lifescience Co., Ltd. Recent Developments/Updates; 7.17.6 Shanghai Chempartner Lifescience Co., Ltd. Competitive Strengths & Weaknesses; 7.18 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd.; 7.18.1 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. Details; 7.18.2 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. Major Business; 7.18.3 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. Biomacromolecule CDMO Product and Services; 7.18.4 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.18.5 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. Recent Developments/Updates; 7.18.6 Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses; 7.19 Genscript Biotech; 7.19.1 Genscript Biotech Details; 7.19.2 Genscript Biotech Major Business; 7.19.3 Genscript Biotech Biomacromolecule CDMO Product and Services; 7.19.4 Genscript Biotech Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.19.5 Genscript Biotech Recent Developments/Updates; 7.19.6 Genscript Biotech Competitive Strengths & Weaknesses; 7.20 Beijing Joinn Biologics Co., Ltd.; 7.20.1 Beijing Joinn Biologics Co., Ltd. Details; 7.20.2 Beijing Joinn Biologics Co., Ltd. Major Business; 7.20.3 Beijing Joinn Biologics Co., Ltd. Biomacromolecule CDMO Product and Services; 7.20.4 Beijing Joinn Biologics Co., Ltd. Biomacromolecule CDMO Revenue, Gross Margin and Market Share (2018-2023); 7.20.5 Beijing Joinn Biologics Co., Ltd. Recent Developments/Updates; 7.20.6 Beijing Joinn Biologics Co., Ltd. Competitive Strengths & Weaknesses
8 Industry Chain Analysis: 8.1 Biomacromolecule CDMO Industry Chain; 8.2 Biomacromolecule CDMO Upstream Analysis; 8.3 Biomacromolecule CDMO Midstream Analysis; 8.4 Biomacromolecule CDMO Downstream Analysis
9 Research Findings and Conclusion
10 Appendix: 10.1 Methodology; 10.2 Research Process and Data Source; 10.3 Disclaimer